Gentium SpA Reaches New 12-Month High at $27.98 (GENT)
Gentium SpA (NASDAQ:GENT)’s share price reached a new 52-week high during mid-day trading on Monday, American Banking News reports. The stock traded as high as $27.98 and last traded at $27.00, with a volume of 127,603 shares traded. The stock had previously closed at $25.11.
GENT has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of Gentium SpA (NASDAQ:GENT) from $20.00 to $35.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks downgraded shares of Gentium SpA (NASDAQ:GENT) from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $23.00 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Gentium SpA (NASDAQ:GENT) from $21.00 to $24.00 in a research note to investors on Wednesday, August 14th. They now have a “buy” rating on the stock.
Gentium SpA has a 52-week low of $6.96 and a 52-week high of $25.98. The stock’s 50-day moving average is $20.29 and its 200-day moving average is $11.69. The company has a market cap of $411.6 million and a price-to-earnings ratio of 85.99.
Gentium SpA (NASDAQ:GENT) last announced its earnings results on Tuesday, August 13th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.14. On average, analysts predict that Gentium SpA will post $0.51 earnings per share for the current fiscal year.
Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacture of defibrotide, a drug based on single-stranded deoxyribonucleic acid (NASDAQ:GENT) derived from pig intestines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.